The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock.
Joao Pedro TeixeiraDavid Perez InglesJordan B BartonJames T DeanPablo GarciaSusan J KunkelPreeyaporn SarangarmNatalie K WeissChristopher L SchaichLaurence W BusseNathan D NielsenPublished in: Trials (2024)
ClinicalTrials.gov NCT05824767. Registered on April 24, 2023.
Keyphrases
- angiotensin ii
- septic shock
- angiotensin converting enzyme
- randomized controlled trial
- vascular smooth muscle cells
- healthcare
- palliative care
- study protocol
- clinical trial
- intensive care unit
- pain management
- stem cells
- systematic review
- mesenchymal stem cells
- combination therapy
- cell therapy
- replacement therapy
- affordable care act
- smoking cessation
- health insurance